Vanguard Group’s Turnstone Biologics TSBX Stock Holding History

Vanguard Group’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-83,926	Closed	-$30.1K	–	4428
2025 Q2	$30.1K	Sell	83,926 -431,161	-84%	-$151K	﹤0.01%	4227
2025 Q1	$211K	Sell	515,087 -63,908	-11%	-$27.2K	﹤0.01%	4064
2024 Q4	$287K	Hold	578,995	–	–	﹤0.01%	4049
2024 Q3	$323K	Hold	578,995	–	–	﹤0.01%	4063
2024 Q2	$1.52M	Buy	578,995 +209,319	+57%	+$598K	﹤0.01%	3649
2024 Q1	$969K	Buy	369,676 +73,064	+25%	+$209K	﹤0.01%	3826
2023 Q4	$755K	Buy	296,612 +188,003	+173%	+$491K	﹤0.01%	3912
2023 Q3	$428K	Buy	+108,609	New	+$968K	﹤0.01%	4103

Vanguard Group's TSBX Position: Q3 2025 in Review

Vanguard Group sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 83,926 shares — an estimated $30.1K sold.

Vanguard Group first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $1.52M in Q2 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Vanguard Group reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Vanguard Group sold 83,926 Turnstone Biologics shares in Q3 2025, an estimated $30.1K.
Vanguard Group first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
Vanguard Group's Turnstone Biologics position peaked at $1.52M in Q2 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.